Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis

Osteoarthritis and Cartilage

Volumn 9, Issue 1, 2001, Pages 14-21

  Johnson, K A ^a,c   Hulse, D A ^b   Hart, R C ^b   Kochevar, D ^b   Chu, Q ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b TEXAS A AND M UNIVERSITY   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Chondroitin sulfate; Glucosamine hydrochloride; Manganese ascorbate; Osteoarthritis; Synovial fluid

Indexed keywords

ASCORBIC ACID; CHONDROITIN SULFATE; EPITOPE; GLUCOSAMINE DERIVATIVE; MANGANESE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE MATRIX; CONTROLLED STUDY; DOG; DRUG SYNOVIAL FLUID LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; KNEE CRUCIATE LIGAMENT; KNEE LIGAMENT INJURY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN ANALYSIS;

EID: 0035125650     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1053/joca.2000.0345     Document Type: Article

References (52)

1. Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3x400 mg/day vs placebo
2. Glucosamine, chondroitin, and manganese ascorbate for degenerative joint disease of the knee or low back: A randomized, double-blind, placebo-controlled pilot study
3. Slow-acting, disease-modifying osteoarthritis agents
4. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee
5. Protective effect of exogenous chondroitin 4,6-sulfate in the acute degradation of articular cartilage in the rabbit
6. Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis
7. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate
8. In vivo chondroprotection and metabolic synergy of glucosamine and chondroitin sulfate
9. Effects of hexosamine derivatives and uronic acid derivatives on glycosaminoglycan metabolism of fibroblast cultures
10. Anti-reactive properties of chondro-protective drugs
11. Chondrocyte-mediated catabolism of aggrecan: Aggrecanase-dependent cleavage induced by interleukin-1 or retinoic acid can be inhibited by glucosamine
12. Oral glycosaminoglycans in treatment of degenerative joint disease in horses
13. Comparison of the anti-inflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis
14. Demonstration of increased proteoglycan turnover in cartilage explants from dogs with experimental arthritis
15. Biosynthesis of collagen and other matrix components by articular cartilage in experimental osteoarthritis
16. A mini review: Proteoglycan aggregate profiles in the Pond-Nuki dog model of osteoarthritis and in canine disuse atrophy
17. Collagenolytic activity and collagen matrix breakdown of the articular cartilage in the Pond-Nuki dog model of osteoarthritis
18. In vivo and in vitro stimulation of chondrocyte biosynthetic activity in early experimental osteoarthritis
19. Increased proteoglycan synthesis in cartilage in experimental canine osteoarthritis does not reflect a permanent change in chondrocyte phenotype
20. Immunological markers of cartilage proteoglycan metabolism in animal and human osteoarthritis
21. Modulation of native chondroitin sulphate structure in tissue development and in disease
22. Proteoglycans in articular cartilage: Changes in aging and in joint disease
23. Chondroitin sulfate and joint disease
24. Changes in glycosaminoglycan epitope levels in knee joint fluid following injury
25. Histomorphological and immunohistochemical evaluation of joint changes in a model of osteoarthritis induced by lateral meniscectomy in sheep
26. Immunohistochemical analysis of 3-B-3(-) and 7-D-4 epitope expression in canine osteoarthritis
27. Anabolic and catabolic markers of proteoglycan metabolism in osteoarthritis
28. Increased release of matrix components from articular cartilage in experimental canine osteoarthritis
29. Altered mechanics of cartilage with osteoarthritis: Human osteoarthritis and an experimental model of joint degeneration
30. Experimental osteoarthritis in dogs: A comparison of the Pond-Nuki and medial arthrotomy methods
31. Management of joint diseases
32. The effect of cosequin in cranial cruciate deficient and reconstructed stifle joints in dogs
33. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue
34. Increased concentrations of proteoglycan components in synovial fluid of patients with acute but not chronic joint disease
35. The power of a statistical test: What does insignificance mean?
36. Results of a survey of small-animal practitioners on the perceived clinical efficacy and safety of an oral nutraceutical
37. Stimulation of proteoglycan production by glucosamine sulfate in chondrocytes isolated from human osteoarthritic articular cartilage in vitro
38. Cartilage stimulatory and antiproteolytic activity is present in sera of dogs treated with a chondroprotective agent
39. Metabolic fate of exogenous chondroitin sulphate in a the experimental animal
40. Pharmacokinetics of glucosamine in the dog and man
41. Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan
42. Monoclonal antibodies that detect biochemical markers of arthritis in humans
43. Glycosaminoglycan sulfation in human osteoarthritis
44. Osteoarthritis in Cynomolgus macaques. II. Detection of modulated proteoglycan epitopes in cartilage and synovial fluid
45. The early molecular natural history of experimental osteoarthritis
46. The quantitation of a native chondroitin sulfate epitope in synovial fluid lavages and articular cartilage from canine experimental osteoarthritis and disuse atrophy
47. Measurement of glycosaminoglycans and keratan sulphate in canine arthropathies
48. Clinical natural history of the post-surgical cruciate deficient canine stifle joint: Year one
49. Synovial fluid chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in arthritic and normal knees
50. Chondroitin and keratan sulphate epitopes, glycosaminoglycans, and hyaluronan in progressive versus non-progressive osteoarthritis
51. The natural history of the anterior cruciate ligament-deficient knee. Changes in synovial fluid cytokine and keratan sulfate concentrations
52. Articular cartilage homeostasis after anterior cruciate ligament reconstruction